Trial record 4 of 36 for: University of Kentucky | Alzheimer's disease | United States, Kentucky

Previous Study | Return to List | Next Study

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

This study has been completed.

Sponsor:

Collaborator:

Pfizer

Information provided by (Responsible Party):

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

ClinicalTrials.gov Identifier:

NCT00575055

First received: December 10, 2007

Last updated: April 20, 2012

Last verified: March 2012

History of Changes

Tracking Information
First Received Date ^ICMJE	December 10, 2007
Last Updated Date	April 20, 2012
Start Date ^ICMJE	December 2007
Primary Completion Date	April 2012 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: December 13, 2007)	Cognitive and Functional [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT00575055 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: March 15, 2012)	Cognitive and Global [ Time Frame: 18 months ] [ Designated as safety issue: No ] Imaging and biochemical biomarkers of disease status [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Original Secondary Outcome Measures ^ICMJE (submitted: December 13, 2007)	Cognitive and Global [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
Official Title ^ICMJE	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.
Brief Summary	This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 200 study sites in the US and Canada will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years. Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 3
Study Design ^ICMJE	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Condition ^ICMJE	Alzheimer's Disease
Intervention ^ICMJE	Drug: Bapineuzumab Comparisons of Bapineuzumab or placebo, given by infusion every 13 weeks for a total of 6 infusions. Drug: Placebo Control Comparisons of Bapineuzumab or placebo, given by infusion every 13 weeks for a total of 6 infusions.
Study Arm (s)	Experimental: Bapineuzumab Dose Intervention: Drug: Bapineuzumab Placebo Comparator: Placebo Dose Intervention: Drug: Placebo Control
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	1121
Completion Date	April 2012
Primary Completion Date	April 2012 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Diagnosis of probable AD Age from 50 to less than 89 Mini-Mental Status Exam score of 16-26 inclusive Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD Stable doses of medications (cholinesterase inhibitors and memantine allowed) Caregiver able to attend all clinic visits with patient Exclusion Criteria: Significant neurological disease other than AD Major psychiatric disorder Significant systemic illness History of stroke or seizure, autoimmune disease, myocardial infarction within the last 2 years Smoking greater than 20 cigarettes per day Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications Prior treatment experimental immunotherapeutics or vaccines for AD Women of childbearing potential Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body
Gender	Both
Ages	50 Years to 88 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT Number ^ICMJE	NCT00575055
Other Study ID Numbers ^ICMJE	ELN115727-302
Has Data Monitoring Committee	Not Provided
Responsible Party	JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Study Sponsor ^ICMJE	JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Collaborators ^ICMJE	Pfizer
Investigators ^ICMJE	Not Provided
Information Provided By	JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Verification Date	March 2012
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top